AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16193299
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of oral calcium daily (groups IB, IIB, IIIB)
Trial: 15130257
Drug: Doxycycline therapy
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline therapy (100 mg)
Trial: 15130257
Drug: Inpatient and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient and outpatient treatment groups
Trial: 11524318
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI) Propofol
Trial: 9239772
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) or oral poliovirus vaccine (OPV)
Trial: 9239772
Drug: COMVAX (Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMVAX (Hib and hepatitis B vaccine)
Trial: 29692602
Drug: Rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (20 mg) alone
Trial: 29692602
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg) alone
Trial: 29692602
Drug: Rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (20 mg) plus Ezetimibe (10 mg)
Trial: 28715142
Drug: Pyridostigmine (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (45 mg, 3 times/day)
Trial: 18466210
Drug: Four daily
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four daily insulin injections
Trial: 17144454
Drug: PYM emulsion
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PYM emulsion applied 3 times daily on the lesions
Trial: 12725542
Drug: Once-daily (OD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (OD) gentamicin 5 mg kg(‐1) d(‐1)
Trial: 12725542
Drug: Conventional 8-hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 8-hourly dosing (TDS) gentamicin 6 mg kg(‐1) d(‐1)
Trial: 3995516
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 40 mg ISDSR
Trial: 3995516
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 40 mg ISDSR (at 07.30 and 13.30 h)
Trial: 31250602
Drug: Intermittent negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent negative pressure therapy (20 minutes, 5 times per week for 4 weeks)
Trial: 26808136
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg or 100 mg daily)
Trial: 22742538
Drug: Immediate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotic therapy with fosfomycin-trometamol 1x3g
Trial: 22742538
Drug: Initial symptomatic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial symptomatic treatment with ibuprofen 3x400mg for 3 days
Trial: 21063142
Drug: Limited intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited intraoperative hydration (no more than 1500 ml in the first 2 hours)
Trial: 16279901
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with lamivudine 100 mg per day for 52 weeks and IFN 5 MIU per day for 16 weeks after the first 8 weeks (group A)
Trial: 16279901
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy 100 mg per day for 52 weeks (group B)
Trial: 16885196
Drug: TNFA (‐308
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFA (‐308 G>A) polymorphism
Trial: 16885196
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IFNGR2 Ex7‐128 C/C and TNFA ‐308 A/A genotypes
Trial: 6388070
Drug: anti-T3 antibody
RxNorm normalized name: Anti-T3 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-T3 antibody (5 mg i.v./day for 14 days)
Trial: 6388070
Drug: steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroid treatment
Trial: 6388070
Drug: anti-T3 antibody
RxNorm normalized name: Anti-T3 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-T3 antibody
Trial: 29595751
Drug: Additional information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional information provided for recommended precancer treatment
Trial: 22167563
Drug: Romiplostim (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (subcutaneous, dose range 0.2‐10 µg/kg)
Trial: 15691277
Drug: ATG induction
RxNorm normalized name: ATGAM Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG induction therapy
Trial: 10721643
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg thrice a day for three days, starting one hour prior to angiography)
Trial: 10721643
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg thrice a day for three days)
Trial: 28451442
Drug: Single steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single steroid injection (followed by later surgery if required)
Trial: 23324512
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention (complete medication history, limited physical examination, provision of guideline-concordant recommendations, and 1-year follow-up)
Trial: 12880499
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sertraline and CBT
Trial: 10642897
Drug: Multivitamin/mineral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin/mineral supplementation (one tablet daily for 10 weeks)
Trial: 8895156
Drug: N‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐3 fatty acids (fish oil) 8 g for 16 weeks
Trial: 6828277
Drug: Ampicillin (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (2-g dose administered intravenously)
Trial: 30121944
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) treatment for 3 weeks during neonatal care
Trial: 27306517
Drug: Chemotherapy (platinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (platinum and pemetrexed) in combination with erlotinib
Trial: 22947843
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control group, n=10)
Trial: 18787352
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (DOC)
Trial: 18787352
Drug: Weekly vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly vinorelbine (VIN)
Trial: 18787352
Drug: Crossover treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover treatment (X-DOC)
Trial: 18787352
Drug: Crossover treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover treatment (X-VIN)
Trial: 16004670
Drug: CC plus
RxNorm normalized name: STATLOCK PICC PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC plus HS (Clomiphene Citrate plus Hormone Supplementation)
Trial: 7795283
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg daily, every other day)
Trial: 2201794
Drug: Topical low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical low dose heparin (0.125 gm./l., 25,000 units per l.)
Trial: 2201794
Drug: Glycine solution
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine solution alone (control)
Trial: 31130666
Drug: KP extract
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KP extract 90 mg/day
Trial: 31130666
Drug: KP extract
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KP extract 180 mg/day
Trial: 24627207
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intraventricular tissue plasminogen activator (TPA) every 12 h (maximum 10 mg)
Trial: 16630999
Drug: lixivaptan 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lixivaptan 10, 30, 75, 150, 250, or 400 mg
Trial: 16630999
Drug: lixivaptan (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lixivaptan (higher doses)
Trial: 10577530
Drug: Photocoagulation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photocoagulation and aspirin treatment
Trial: 8561333
Drug: Continuous spinal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous spinal anesthesia (CSA) with 5 mg of 0.5% hyperbaric bupivacaine, followed by optional reinjection of 2.5 mg every 5 min
Trial: 8561333
Drug: Single-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spinal anesthesia (SDSA) with 10-15 mg of 0.5% hyperbaric bupivacaine
Trial: 8561333
Drug: Single-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spinal anesthesia (SDSA)
Trial: 2008876
Drug: 4-6 140-mL
RxNorm normalized name: gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-6 140-mL cups filtered decaffeinated coffee per day and 75 mg caffeine pills
Trial: 2008876
Drug: 4-6 140-mL
RxNorm normalized name: gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-6 140-mL cups filtered decaffeinated coffee per day and placebo pills
Trial: 6351333
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (10 mg) after intramuscular atropine (0.6 mg)
Trial: 6351333
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (control) after intramuscular atropine (0.6 mg)
Trial: 29401529
Drug: Tissue flossing
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue flossing (3 treatments lasting 2 minutes each)
Trial: 29231589
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of soft capsule of Vitamin E, once a day for 28 days
Trial: 14617718
Drug: acetylcholinesterase inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetylcholinesterase inhibitor (donepezil)
Trial: 9039344
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (up to 0.25 U/kg/week in daily doses)
Trial: 8249050
Drug: Nicotine skin
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine skin patches (three different doses applied to different groups)
Trial: 1916494
Drug: Metronidazole 20
RxNorm normalized name: metronidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 20 mg/kg
Trial: 1916494
Drug: Metronidazole 10
RxNorm normalized name: metronidazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 10 mg/kg
Trial: 1916494
Drug: Metronidazole (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (combined 20 mg/kg and 10 mg/kg)
Trial: 393035
Drug: Oral retinoid
RxNorm normalized name: tretinoin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral retinoid (25 mg three times a day for six weeks)
Trial: 30514775
Drug: DC–CIK infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC–CIK infusions
Trial: 22855271
Drug: Vardenafil (0.3-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (0.3-3 mg/kg) in rats; administered orally 30 min before testing.
Trial: 22855271
Drug: Vardenafil (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (10-20 mg) in humans; administered 85 min before testing.
Trial: 22855271
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in humans; administered 85 min before testing.
Trial: 8210543
Drug: Thymopentin 50
RxNorm normalized name: Thymopentine
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin 50 mg s.c. every other day, after irradiation for at least 6 cycles of 4 weeks each
Trial: 28293470
Drug: ABT‐436 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐436 800 mg QD
Trial: 26430826
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (2 capsules/day for 8 weeks)
Trial: 26430826
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules/day for 8 weeks)
Trial: 21830124
Drug: Chemotherapeutics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutics plus verapamil infusion
Trial: 21830124
Drug: Targeted intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Targeted intra-arterial infusion (control)
Trial: 19219314
Drug: Radial shockwave
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shockwave treatment (three applications, once a week)
Trial: 17309575
Drug: Midodrine hydrochloride
RxNorm normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine hydrochloride (MID) at 4 mg/day
Trial: 17309575
Drug: L-threo-3,4-dihydroxyphenylserine (L-DOPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threo-3,4-dihydroxyphenylserine (L-DOPS) at 400 mg/day
Trial: 12378829
Drug: Strontium salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strontium salt (oral administration at low dosage)
Trial: 12378829
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose intermittent fluoride therapy
Trial: 12378829
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor I and other growth factors
Trial: 7665724
Drug: Mitoxantrone (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (cumulative dose of 96 mg/m2)
Trial: 2501110
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) Buserelin (300 micrograms three times a day)
Trial: 2501110
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) Buserelin implant (6.6 mg Buserelin)
Trial: 782796
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol (400 mug daily)
Trial: 26039125
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity lifestyle modification (LILM) program for 6 months, including 4 interactive group discussion sessions and weekly phone contact with volunteer counselors.
Trial: 23344468
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose prednisolone (1 mg/Kg/dose 24 h before surgery)
Trial: 23344468
Drug: 5-day prednisolone
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day prednisolone (1 mg/Kg/day before operation)
Trial: 20715901
Drug: Sourdough prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sourdough prepared with L. plantarum
Trial: 17081831
Drug: Universal-free school
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal-free school breakfast offered in treatment schools for three consecutive school years (2000-2001 to 2002-2003)
Trial: 15466731
Drug: Electrohydraulic high-energy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrohydraulic high-energy shock waves treatment
Trial: 7970842
Drug: Fluoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10 mg p.o. daily for 7 days pre-operatively)
Trial: 3315282
Drug: (2"R)-4'-O-tetrahydropyranyladriamycin (THP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) 10-55 mg/m2 administered by i.v. bolus injection daily for acute leukemia
Trial: 3315282
Drug: (2"R)-4'-O-tetrahydropyranyladriamycin (THP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) administered according to three different schedules for malignant lymphoma: daily, weekly or once every 3-4 weeks
Trial: 29228206
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment group (n = 33)
Trial: 29228206
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment group (n = 34)
Trial: 27927951
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg S44819
Trial: 27927951
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg S44819
Trial: 21109115
Drug: β-blocker treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker treatment initiated >1 to 4 weeks before surgery
Trial: 21109115
Drug: β-blocker treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker treatment initiated >4 weeks before surgery
Trial: 21109115
Drug: β-blocker treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker treatment initiated <1 week before surgery
Trial: 17511802
Drug: Chemotherapy every
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy every 4 weeks (cisplatin-paclitaxel or carboplatin-paclitaxel)
Trial: 17511802
Drug: Chemotherapy every
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy every 3 weeks (cisplatin-paclitaxel or carboplatin-paclitaxel)
Trial: 17511802
Drug: Early-stage disease
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-stage disease (chemotherapy every 4 weeks)
Trial: 12714865
Drug: lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 20 mg o.d.
Trial: 12714865
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg o.d.
Trial: 12714865
Drug: lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 20 mg o.d. (responders only)
Trial: 12714865
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg o.d. (responders only)
Trial: 8652784
Drug: Intelligent control
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intelligent control system for insulin dosage recommendations
Trial: 6238315
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg administered intravenously
Trial: 6238315
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg associated with noramidopyrine
Trial: 28171855
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (n = 98)
Trial: 28171855
Drug: Standard-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose group (n = 65)
Trial: 26048730
Drug: TXA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA 500 mg intra-articular injection
Trial: 26048730
Drug: Saline intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline intra-articular injection (control)
Trial: 23740284
Drug: Dobutamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (5 mcg/kg/min fixed-dose)
Trial: 12093655
Drug: Topical IOP-lowering
RxNorm normalized name: Avena sativa flowering top
DrugBank: Avena sativa flowering top (DB14253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical IOP-lowering treatment (mainly beta-blockers)
Trial: 12093655
Drug: Topical IOP-lowering
RxNorm normalized name: Avena sativa flowering top
DrugBank: Avena sativa flowering top (DB14253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical IOP-lowering treatment (n = 33)
Trial: 10362413
Drug: 546C88 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 546C88 at 1 mg/kg/hr
Trial: 10362413
Drug: 546C88 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 546C88 at 2.5 mg/kg/hr